Izalontamab (SI-B001), a novel EGFR/HER3 bispecific monoclonal antibody, was well-tolerated and exhibited preliminary ...
A positive trend in overall survival was observed, favoring sacituzumab govitecan over chemotherapy, though data is still ...
Dr. Strosberg discusses the safety profile and long-term toxicities of 212Pb-DOTAMTATE treatment, highlighting renal issues ...
In an interview with Targeted Oncology at the 2025 North American Neuroendocrine Tumor Society (NANETS) Symposium, Michael ...
The segment concludes that long-term data reinforce the durability and clinical relevance of combination immunotherapy, ...
A panelist discusses how both lurbinectedin and tarlatamab remain important in the management of relapsed small cell lung ...
A panelist discusses how novel bispecifics and ADCs signal a more hopeful future for ES-SCLC management. A panelist discusses how the therapeutic landscape of extensive-stage small cell lung cancer ...
The DISCUS trial demonstrated improved QOL with 3 cycles of chemotherapy compared to 6 cycles in advanced urothelial cancer patients. Both treatment arms showed similar overall survival and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback